Literature DB >> 28338197

Predictive value and modeling analysis of MSCT signs in gastrointestinal stromal tumors (GISTs) to pathological risk degree.

J-K Wang1.   

Abstract

OBJECTIVE: By analyzing MSCT (multi-slice computed tomography) signs with different risks in gastrointestinal stromal tumors, this paper aimed to discuss the predictive value and modeling analysis of MSCT signs in GISTs (gastrointestinal stromal tumor) to pathological risk degree. PATIENTS AND METHODS: 100 cases of primary GISTs with abdominal and pelvic MSCT scan were involved in this study. All MSCT scan findings and enhanced findings were analyzed and compared among cases with different risk degree of pathology. Then GISTs diagnostic model was established by using support vector machine (SVM) algorithm, and its diagnostic value was evaluated as well.
RESULTS: All lesions were solitary, among which there were 46 low-risk cases, 24 medium-risk cases and 30 high-risk cases. For all high-risk, medium-risk and low-risk GISTs, there were statistical differences in tumor growth pattern, size, shape, fat space, with or without calcification, ulcer, enhancement method and peritumoral and intratumoral vessels (p<0.05). However, there were no statistical differences in the location of tumor and CT value at each period (plain scan, arterial phase, venous phase) (p>0.05). The apparent difference lied in plain scan, arterial phase and venous phase for each risk degree. The diagnostic accuracy of SVM diagnostic model established with 10 imaging features as indexes was 70.0%, and it was especially reliable when diagnosing GISTs of high or low risk.
CONCLUSIONS: Preoperative analysis of MSCT features is clinically significant for its diagnosis of risk degree and prognosis; GISTs diagnostic model established on the basis of SVM possesses high diagnostic value.

Entities:  

Mesh:

Year:  2017        PMID: 28338197

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  [A radiomics-based model for differentiation between benign and malignant gastrointestinal stromal tumors].

Authors:  Wenhua Zhang; Tao Chen; Minghui Zhang; Pingping Liu; Zhentai Lu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

2.  Preoperative CT feature of incomplete overlying enhancing mucosa as a high-risk predictor in gastrointestinal stromal tumors of the stomach.

Authors:  Gang Peng; Bingcang Huang; Xiaodan Yang; Maohua Pang; Na Li
Journal:  Eur Radiol       Date:  2020-10-30       Impact factor: 5.315

3.  Computed-Tomography-Based Radiomics Model for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors Preoperatively: A Multi-Classifier and Multicenter Study.

Authors:  Minhong Wang; Zhan Feng; Lixiang Zhou; Liang Zhang; Xiaojun Hao; Jian Zhai
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Preoperative prediction of gastrointestinal stromal tumors with high Ki-67 proliferation index based on CT features.

Authors:  Cai-Wei Yang; Xi-Jiao Liu; Lian Zhao; Feng Che; Yuan Yin; Hui-Jiao Chen; Bo Zhang; Min Wu; Bin Song
Journal:  Ann Transl Med       Date:  2021-10

5.  Preoperative CT-Based Deep Learning Model for Predicting Risk Stratification in Patients With Gastrointestinal Stromal Tumors.

Authors:  Bing Kang; Xianshun Yuan; Hexiang Wang; Songnan Qin; Xuelin Song; Xinxin Yu; Shuai Zhang; Cong Sun; Qing Zhou; Ying Wei; Feng Shi; Shifeng Yang; Ximing Wang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

6.  Malignancy risk of gastrointestinal stromal tumors evaluated with noninvasive radiomics: A multi-center study.

Authors:  Yun Wang; Yurui Wang; Jialiang Ren; Linyi Jia; Luyao Ma; Xiaoping Yin; Fei Yang; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

7.  MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors.

Authors:  Haijia Mao; Bingqian Zhang; Mingyue Zou; Yanan Huang; Liming Yang; Cheng Wang; PeiPei Pang; Zhenhua Zhao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.